Abstract:Due to fast transmission and various circulating SARS-CoV-2 variants, a significant increase of coronavirus 2019 infection cases with acute respiratory symptoms has prompted worries about the efficiency of current vaccines. The possible evasion from vaccine immunity urged scientists to identify novel therapeutic targets for developing improved vaccines to manage worldwide COVID-19 infections. Our study sequenced pooled peripheral blood mononuclear cells transcriptomes of SARS-CoV-2 patients with moderate and critical clinical outcomes to identify novel potential host receptors and biomarkers that can assist in developing new translational nanomedicines and vaccine therapies. The dysregulated signatures were associated with humoral immune responses in moderate and critical patients, including B-cell activation, cell cycle perturbations, plasmablast antibody processing, adaptive immune responses, cytokinesis, and interleukin signaling pathway. The comparative and longitudinal analysis of moderate and critically infected groups elucidated diversity in regulatory pathways and biological processes. Several immunoglobin genes (IGLV9-49, IGHV7-4, IGHV3-64, IGHV1-24, IGKV1D-12 , and IGKV2-29) , ribosomal proteins (RPL29, RPL4P2, RPL5 , and RPL14) , inflammatory response related cytokines including Tumor Necrosis Factor (TNF, TNFRSF17 , and TNFRSF13B) , C-C motif chemokine ligands (CCL3, CCL25, CCL4L2, CCL22 , and CCL4) , C-X-C motif chemokine ligands (CXCL2, CXCL10 , and CXCL11) and genes related to cell cycle process and DNA proliferation ( MYBL2, CDC20, KIFC1 , and UHCL1 ) were significantly upregulated among SARS-CoV-2 infected patients. 60S Ribosomal protein L29 (RPL29) was a highly expressed gene among all COVID-19 infected groups. Our study suggested that identifying differentially expressed genes (DEGs) based on disease severity and onset can be a powerful approach for identifying potential therapeutic targets to develop effective drug delivery systems against SARS-CoV-2 infections. As a result, potential therapeutic targets, such as the RPL29 protein, can be tested in vivo and in vitro to develop future mRNA-based translational nanomedicines and therapies to combat SARS-CoV-2 infections.

Diagnostic Applications for RNA-Seq Technology and Transcriptome Analyses in Human Diseases Caused by RNA Viruses

Microfluidic Device-Based Virus Detection and Quantification in Future Diagnostic Research: Lessons from the COVID-19 Pandemic

Viral and Host Transcriptomes in SARS-CoV-2-Infected Human Lung Cells

Introduction to RNA Vaccines Post COVID-19

Engineering CRISPR/Cas13 System Against RNA Viruses: from Diagnostics to Therapeutics

Next-Generation Sequencing: a new avenue to understand viral RNA-protein interactions

New perspective of small-molecule antiviral drugs development for RNA viruses

Identification of Novel Therapeutic Candidates Against SARS-CoV-2 Infections: An Application of RNA Sequencing Toward mRNA Based Nanotherapeutics

RNA Sequencing in Disease Diagnosis

Efficient and accurate detection of viral sequences at single-cell resolution reveals putative novel viruses perturbing host gene expression

Non-coding RNAs Expression in SARS-CoV-2 Infection: Pathogenesis, Clinical Significance, and Therapeutic Targets

Next‐Generation Sequencing Methods for Near‐Real‐Time Molecular Epidemiology of HIV and HCV

The Power of Using Novel Nanopore Sequencing Technology for Diagnosis, Genomic and Pathological Studies of Covid-19

Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients

A Game of Infection – Song of Respiratory Viruses and Interferons

SARS-CoV-2 genomic diversity and the implications for qRT-PCR diagnostics and transmission

The Applications of Nanopore Sequencing Technology in Animal and Human Virus Research

Application of next-generation sequencing technologies in virology

The Human Virome: Viral Metagenomics, Relations with Human Diseases, and Therapeutic Applications

Therapeutic and Prophylactic Potential of Small Interfering RNAs Against Severe Acute Respiratory Syndrome

Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions